{"name":"Mimetogen Pharmaceuticals USA, Inc.","slug":"mimetogen-pharmaceuticals-usa-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"MIM-D3 Ophthalmic Solution","genericName":"MIM-D3 Ophthalmic Solution","slug":"mim-d3-ophthalmic-solution","indication":"Treatment of Leber congenital amaurosis due to RPE65 mutations","status":"phase_3"}]},{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Tavilermide ophthalmic solution","genericName":"Tavilermide ophthalmic solution","slug":"tavilermide-ophthalmic-solution","indication":"Dry eye disease","status":"phase_3"}]}],"pipeline":[{"name":"MIM-D3 Ophthalmic Solution","genericName":"MIM-D3 Ophthalmic Solution","slug":"mim-d3-ophthalmic-solution","phase":"phase_3","mechanism":"MIM-D3 Ophthalmic Solution is a small molecule that targets the rhodopsin kinase (GRK1) to treat retinal diseases.","indications":["Treatment of Leber congenital amaurosis due to RPE65 mutations"],"catalyst":""},{"name":"Tavilermide ophthalmic solution","genericName":"Tavilermide ophthalmic solution","slug":"tavilermide-ophthalmic-solution","phase":"phase_3","mechanism":"Tavilermide is a small-molecule integrin antagonist that inhibits cell adhesion and migration by blocking integrin-mediated interactions, reducing inflammatory cell infiltration in ocular tissues.","indications":["Dry eye disease","Ocular inflammation"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMicEFVX3lxTE8zZlhUOWJGNGVfWW9UWUJvWEZDQV8xbkVQN2pHNHZDd1RLTy03WFNXbFpqTVNnRUY4MnZDblQ1Sm1oOE9UaFZpWk1mQUxHUVBfU1JvVnJ3S1NRSVZxZWZWVzdVM0RlWDZxUWs2bUlfN1c?oc=5","date":"2016-07-12","type":"regulatory","source":"pharmaphorum","summary":"Shire dry eye drug approved in US - pharmaphorum","headline":"Shire dry eye drug approved in US","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxQOEdXeGtobUZHSXprSFdsTmFqdFcxYnczUElYUlhiOU4tRzhpY2J3U1RBb0s0STdUWGpNMmFNZXZhYkFzU2tGOU5NUTZ1ZUoyc2k0N19nb2twZVhPTzJhU2cySk1zbU1sYmtXRW1fbXBVQndXVW5fdUl5cFFjMnRRdTN5R01NejB2eGtUOFVoUi1VR2FWVnVIMzhXSlZiZFV0?oc=5","date":"2015-12-03","type":"pipeline","source":"McGill University","summary":"Treatment for dry eye disease based on McGill research - McGill University","headline":"Treatment for dry eye disease based on McGill research","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAJBVV95cUxOVmtRd2trbFdCdzdvbUZQaGt5Vk5yTjNjc3VWWjNSdnZuTGliQmJldUNDNDhKbjVTdHllejRfN1dXMTJFZU9sUnZNTzFlODRvUWVKZ2k3X1poUUVJSmd6TkNNUU53ZlVIZHZPdWR5b25RVXFvdTBrYVU0OG9uRmNuZGk5djVnZmFPN1dORWZBX3ZYTmw2TGNPSndiVmhPV3VGX294OVAtWDVhZTBMX2hfdENfcFRQcTNYcEhWdEdlWjRWRThud0kweUZObUxhaF8wMHFmODIwVXJrX0dWNFhyQkJDcFdFTFUzQkh2Nk9SNkZSWGo0RWVpSXBOUHFJUUwxZ0FoSGkyaEFYV2dRRlU1YWs2akM3MExqWXFJQncwZi00VENKMmdtcw?oc=5","date":"2015-11-04","type":"pipeline","source":"prnewswire.com","summary":"Allergan Enters Into Licensing Agreement with Mimetogen Pharmaceuticals to Develop and Commercialize Tavilermide (MIM-D3) Topical Dry Eye Treatment - prnewswire.com","headline":"Allergan Enters Into Licensing Agreement with Mimetogen Pharmaceuticals to Develop and Commercialize Tavilermide (MIM-D3","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}